Literature DB >> 18246865

Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation.

Xiaobin Xie1, Vickram Ramkumar, Linda A Toth.   

Abstract

This review will examine how dopamine, a monoamine neurotransmitter, and adenosine, a neuromodulator, regulate behavioral activation, primarily as reflected by locomotor activity, in rodents. Complex interactions among 2 major types of adenosine receptors (A1AR and A2AAR) and 2 dopamine receptors (D1R and D2R) occur due to physical interactions that alter their ligand-binding properties and subsequent effects on common postreceptor signaling molecules. The output from these interactions in striatum modulates neurotransmission and subsequently influences spontaneous locomotor activity. Caffeine is a nonselective adenosine receptor antagonist that blocks 2 major types of adenosine receptors, A1AR and A2AAR, in the brain. Pharmacologic manipulation of these receptors with drugs such as caffeine offers potential therapeutic benefit for treatment of Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18246865

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  13 in total

1.  Adenosine modulates excitatory synaptic transmission and suppresses neuronal death induced by ischaemia in rat spinal motoneurones.

Authors:  Nobuyuki Miyazaki; Terumasa Nakatsuka; Daisuke Takeda; Kazuhiro Nohda; Kazuhide Inoue; Munehito Yoshida
Journal:  Pflugers Arch       Date:  2008-06-27       Impact factor: 3.657

2.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

3.  Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.

Authors:  Hsien-yang Lee; Junko Nakayama; Ying Xu; Xueliang Fan; Maha Karouani; Yiguo Shen; Emmanuel N Pothos; Ellen J Hess; Ying-Hui Fu; Robert H Edwards; Louis J Ptácek
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

4.  Reproducibility of non-invasive a1 adenosine receptor quantification in the rat brain using [(18)F]CPFPX and positron emission tomography.

Authors:  Tina Kroll; David Elmenhorst; Angela Weisshaupt; Simone Beer; Andreas Bauer
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

5.  Adenosine receptor antagonists and behavioral activation in NF-kappaB p50 subunit knockout mice.

Authors:  Xiaobin Xie; Yashanad Mhaskar; Lydia A Arbogast; Rita A Trammell; Larry F Hughes; Linda A Toth
Journal:  Life Sci       Date:  2009-06-07       Impact factor: 5.037

Review 6.  The buzz on caffeine in invertebrates: effects on behavior and molecular mechanisms.

Authors:  Julie A Mustard
Journal:  Cell Mol Life Sci       Date:  2013-10-26       Impact factor: 9.261

Review 7.  Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.

Authors:  Marla Rivera-Oliver; Manuel Díaz-Ríos
Journal:  Life Sci       Date:  2014-02-13       Impact factor: 5.037

8.  Influence of chronic caffeine on MDMA-induced behavioral and neuroinflammatory response in mice.

Authors:  Jessica Ruiz-Medina; Ana Pinto-Xavier; Marta Rodríguez-Arias; José Miñarro; Olga Valverde
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

9.  Caffeine stimulates locomotor activity in the mammalian spinal cord via adenosine A1 receptor-dopamine D1 receptor interaction and PKA-dependent mechanisms.

Authors:  JeanMarie Acevedo; Alexandra Santana-Almansa; Nikol Matos-Vergara; Luis René Marrero-Cordero; Ernesto Cabezas-Bou; Manuel Díaz-Ríos
Journal:  Neuropharmacology       Date:  2015-10-19       Impact factor: 5.250

10.  CD73 is a major regulator of adenosinergic signalling in mouse brain.

Authors:  Natalia Kulesskaya; Vootele Võikar; Marjaana Peltola; Gennady G Yegutkin; Marko Salmi; Sirpa Jalkanen; Heikki Rauvala
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.